Abstract: Provided is a technique for improving the productivity in a method for producing a compound I or a pharmaceutically acceptable salt thereof. This method for producing the compound I comprises: a step for preparing a compound 16 solution by deprotecting a compound 10-R3 in a solvent; and a step for adding a compound 15 to the compound 16 solution without isolating the compound 16 and synthesizing the compound I in the presence of a condensing agent.

Abstract: An object of the present invention is to provide a therapeutic agent for fatty liver diseases. The above object can be achieved by a therapeutic agent for a fatty liver disease, comprising a compound represented by the following formula (1): or a pharmaceutically acceptable salt thereof.

Abstract: An object of the present invention is to provide a therapeutic agent for fatty liver diseases. The above object can be achieved by a therapeutic agent for a fatty liver disease, comprising a compound represented by the following formula (1): or a pharmaceutically acceptable salt thereof.

Abstract: Provided is a medicinal composition having excellent stability, the medicinal composition comprising 3-{[(2S)-2-amino-2-carboxyethyl]carbamoylamino}-5-chloro-4-methylbenzenesulfonic acid, a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein the medicinal composition has a pH of 8.0 or less.

Abstract: A medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis, said medicinal composition comprising 3-{[(2S)-2-amino-2-carboxyethyl]carmaboylamino}-5-chloro-4-methylbenzenesulfonic acid or a pharmaceutically acceptable salt thereof, or a solvate of the same which is to be administered by a predefined route in a predefined dosage. According to the present invention, it is possible to provide a prophylactic or therapeutic agent for secondary hyperparathyroidism under maintenance dialysis, said agent showing reduced side effects or no significant accumulation. This medicinal agent allows easy administration management and has a high safety compared with conventional products.

Abstract: The present invention provides a method for determining the likelihood of colorectal cancer development in a human ulcerative colitis patient, the method including: a measurement step of measuring methylation rates of one or more CpG sites present in specific differentially methylated regions in DNA recovered from a biological sample collected from the human ulcerative colitis patient; and a determination step of determining the likelihood of colorectal cancer development in the human ulcerative colitis patient based on average methylation rates of the differentially methylated regions which are calculated based on the methylation rates measured in the measurement step and a preset reference value or a preset multivariate discrimination expression, in which the reference value is a value for identifying a cancerous ulcerative colitis patient and a non-cancerous ulcerative colitis patient, which is set for the methylation rate of each differentially methylated region, and the multivariate discrimination expres

Abstract: A medical support system includes a first transmitting antenna attached to a body surface that transmits a first transmitting wave, and a reflector that is present in the body and reflects the first transmitting wave transmitted from the first transmitting antenna. A first receiving antenna attached to the body surface receives the first transmitting wave transmitted from the first transmitting antenna and a reflected wave reflected by the reflector, and a location estimation device estimates the passage of the reflector in the body based on changes in the respective phases of the first transmitting wave received by the first receiving antenna and the reflected wave, at time t and time t+?t.

Abstract: A new agent for the treatment of a corneal epithelium disorder, which acts directly on corneal epithelial cells, is provided. Disclosed is an agent for the treatment of a corneal epithelium disorder, the agent comprising a compound of Formula (1) or a salt thereof as an active ingredient: wherein A is an aromatic ring, a heterocyclic ring, or an aliphatic ring; R2, R3, and R4, which may be identical or different, each independently are, for example, a hydrogen atom, a halogen atom; B is an aromatic ring which may have a substituent, a heterocyclic ring which may have a substituent, or an aliphatic ring which may have a substituent; —X—, —Y—, and —Z—, which may be identical or different, each independently are O—, —NH—, —NR5—, —S—, —SO—, —SO2—, —CH2—, —CR6R7—, or —CO—; and —W— is —NR1—, —O—, or —CR8R9—.

Abstract: A medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis, said medicinal composition comprising 3-{[(2S)-2-amino-2-carboxyethyl]carmaboylamino}-5-chloro-4-methylbenzenesulfonic acid or a pharmaceutically acceptable salt thereof, or a solvate of the same which is to be administered by a predefined route in a predefined dosage. According to the present invention, it is possible to provide a prophylactic or therapeutic agent for secondary hyperparathyroidism under maintenance dialysis, said agent showing reduced side effects or no significant accumulation. This medicinal agent allows easy administration management and has a high safety compared with conventional products.

Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. The compound has a superior TRPA1 antagonist activity, and can provide a medicament useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.

Abstract: Compounds of represented by formula (I): wherein each symbol is defined herein and pharmaceutically acceptable salts thereof exhibit TRPA1 antagonist activity and are useful as TRPA1 antagonists and the prophylaxis or treatment of diseases involving TRPA1.

Abstract: Provided is a compound having ?4 integrin inhibitory action. The compound is a sulfonamide derivative represented by the following formula (I), or pharmaceutically acceptable salt thereof: where R1 to R5, e to h, D, and B represent those as described in the specification.

Abstract: The present invention provides a method for determining the likelihood of sporadic colorectal cancer development, the method including: a measurement step of measuring methylation rates of one or more CpG sites present in specific differentially methylated regions, in DNA recovered from a biological sample collected from a human subject; and a determination step of determining the likelihood of sporadic colorectal cancer development in the human subject, based on average methylation rates of the differentially methylated regions which are calculated based on the methylation rates measured and a preset reference value or a preset multivariate discrimination expression, in which the reference value is a value for identifying a sporadic colorectal cancer patient and a non-sporadic colorectal cancer patient, which is set for the average methylation rate of each differentially methylated region, and the multivariate discrimination expression includes, as variables, average methylation rates of one or more differen

Abstract: The present invention includes cilastatin or a pharmaceutically acceptable salt thereof as an active component and a suppressant for renal impairment or inner ear disorders, induced via megalin by at least one megalin ligand which is selected from the group consisting of polymyxins, aminoglycoside antibiotics, glycopeptide antibiotics, cisplatin, and pharmaceutically acceptable salts thereof.

Abstract: The present invention provides a method for determining the likelihood of colorectal cancer development in a human ulcerative colitis patient, the method including: a measurement step of measuring methylation rates of one or more CpG sites present in specific differentially methylated regions in DNA recovered from a biological sample collected from the human ulcerative colitis patient; and a determination step of determining the likelihood of colorectal cancer development in the human ulcerative colitis patient based on average methylation rates of the differentially methylated regions which are calculated based on the methylation rates measured in the measurement step and a preset reference value or a preset multivariate discrimination expression, in which the reference value is a value for identifying a cancerous ulcerative colitis patient and a non-cancerous ulcerative colitis patient, which is set for the methylation rate of each differentially methylated region, and the multivariate discrimination expres

Abstract: A multi-cell container includes a bag of substantially flat shape made of flexible film, a partition wall as a separable seal welding opposite inner surfaces of the bag and dividing an inner space of the bag into a plurality of compartments and an inlet-outlet port located at a periphery of the bag so as to be opened to one of the plurality of compartments for introduction and/or discharge of liquid. The partition wall has a horizontal section extending in a direction along the bottom of the bag and a vertical section bent therefrom and extending to the topside of the bag. A first larger volume compartment is formed on one side of the partition wall adjacent the bag bottom and a second smaller volume compartment is formed on the other side of the partition wall. The inlet-outlet port is opened to the first chamber.

Abstract: Provided is a compound having ?4 integrin inhibitory action. The compound is a sulfonamide derivative represented by the following formula (I), or pharmaceutically acceptable salt thereof: where R1 to R5, e to h, D, and B represent those as described in the specification.

Abstract: Compounds of represented by formula (I): wherein each symbol is defined herein and pharmaceutically acceptable salts thereof exhibit TRPA1 antagonist activity and are useful as TRPA1 antagonists and the prophylaxis or treatment of diseases involving TRPA1.

Abstract: Provided is a pharmaceutical composition for treating ulcerative colitis, comprising a compound represented by a formula (1) or a pharmaceutically acceptable salt thereof, wherein the compound or the pharmaceutically acceptable salt is administered in an amount of 600 mg or more per day to an ulcerative colitis patient.

Abstract: A composition containing a compound represented by General Formula (I) below (see the definition in the specification for the symbols in the formula) or a salt thereof has an excellent CaSR agonistic effect and provides a pharmaceutical agent, a CaSR agonistic agent, a prophylactic or therapeutic agent for a disease that can be ameliorated through CaSR activation as well as seasonings and an agent for imparting kokumi.